ScholarIQanswers from OpenAlex

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

PaperCitations, authors & open-access status

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer have?

ScholarIQcitation count

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has 312 citations in the OpenAlex counts ScholarIQ stores.

When was Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer published?

ScholarIQyear

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has 2019 year in the ScholarIQ index.

What is the open-access status of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

ScholarIQoa status

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer has green oa status in the ScholarIQ index.

What is the DOI of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

ScholarIQdoi

The DOI for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

What is the PMID of Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

ScholarIQpmid

The PMID for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

What is the OpenAlex record for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer?

ScholarIQopenalex

The OpenAlex for Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial